GLICOPROTEIN (GP) IIb/IIIa INHIBITORS FOR ACUTE STROKE TREATMENT

Abstract

The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.

• Stroke
• GP IIb/IIIa receptors
• Cerebral ischemia
• Thrombosis